Interpretation of pulmonary function tests (PFTs) is essentially based on comparing measured flows or volumes against their predicted values derived from healthy individuals from similar populations ([@bib1]--[@bib3]). Generally, forced vital capacity (FVC), forced expiratory volume in 1 second (FEV~1~), FEV~1~/FVC ratio, and total lung capacity (TLC; obtained by body plethysmography, gas dilution, or other methods) are the key variables used to interpret pulmonary function. Measuring or computing residual volume (RV), functional residual capacity (FRC), and TLC is technically complicated and more challenging. Although this may limit the use of these tests in clinical practice, in particular situations they become essential for characterizing the physiological state or impairment ([@bib4]).

For each lung function measurement or calculated parameter, values at the fifth percentile from healthy sex- and race-referenced individuals define what is considered the lower limit of normal (LLN) ([@bib1], [@bib5]). This approach, similar to the one using the *z-*scores or "standardized" variables (i.e., the number of standard deviations away from the mean), assumes that the parameters are part of a normal distribution, which is, in fact, rarely the case. When the frequency distribution is skewed, a nonparametric technique such as the 95th-percentile method can be used instead ([@bib6]). Nevertheless, unlike percent predicted values, *z-*scores are free from bias induced by age, height, sex, ethnicity, or race and therefore are particularly useful in defining the LLNs and increasingly recommended in the interpretation of PFTs ([@bib2]).

Two of the most widely used predictive equations are represented by the Third National Health and Nutrition Examination Survey ([@bib7]) and by predicted reference values for spirometry derived and published by the Global Lung Initiative (GLI) ([@bib2]). The latter equations are updated and more comprehensive than previous prediction sets and are recommended for implementation in PFT laboratories worldwide; yet, significant adoption variability persists. In addition, significant variability remains in the way PFTs are interpreted, including the best way to define ventilatory impairments beyond obstruction and (possible) restriction.

To address these shortcomings, to potentially enhance the diagnostic accuracy and value of PFTs, and to determine which patients need additional lung volume determinations, in this study, we evaluated the utility of an alternative spirometric parameter called the "area under the expiratory flow--volume curve" (AEX) ([@bib8]--[@bib11]). The AEX is the actual integral function of the variable flow (on the *y*-axis) versus expiratory volume (on the *x*-axis) during a forced exhalation maneuver from TLC to RV and is expressed in L^2^⋅s^−1^ ([Figure 1](#fig1){ref-type="fig"}). In this study, AEX was obtained from the proprietary software algorithm of the spirometry equipment's manufacturer. We have previously shown that, in the absence of AEX, several computations based on instantaneous flows may be very close AEX approximations, which could be useful in interpreting observed functional impairment and could potentially be valuable as surrogate measurements ([@bib12]).

![Depiction of the area under the expiratory flow--volume curve (AEX; in L^2^·s^−1^), the integral function of instantaneous flows against expired volume during a forced respiratory maneuver. AEX = area under the expiratory flow--volume curve.](AnnalsATS.201908-613OC_f1){#fig1}

Methods
=======

This data set included a cohort of 15,308 consecutive, best-trial, acceptable, prebronchodilator spirometry tests performed in the Cleveland Clinic PFT Laboratory. The extraction criteria were *1*) prespecified time period of 10 years, *2*) spirometry tests with available AEX values (the largest value was extracted), and *3*) all consecutive tests done in adult subjects who underwent same-day spirometry and lung volume testing by either body plethysmography ([@bib13]) or a helium dilution technique ([@bib14]).

Spirometry was performed following the American Thoracic Society (ATS) standards ([@bib1], [@bib5], [@bib15]). Body plethysmography and helium dilution techniques were used to assess lung volumes per ATS/European Respiratory Society (ERS) standards and criteria ([@bib1], [@bib4], [@bib6]). Spirometry, body plethysmography, and helium dilution technique determinations were performed using a Jaeger Master Lab Pro system. Reference values from the GLI were used for spirometry interpretation ([@bib2]). For lung volumes, the reference values used were those of Crapo and colleagues ([@bib16]). Diagnostic performance of AEX was assessed by the test's receiver operating characteristic curve, accuracy, and reclassification rates. As per the ATS/ERS simplified diagnostic algorithm ([@bib6]), normal pattern was defined by normal FVC and normal FEV~1~/FVC ratio (FVC \> FVC~LLN~ and FEV~1~/FVC \> FEV~1~/FVC~LLN~); obstruction was diagnosed either as FEV~1~/FVC \< FEV~1~/FVC~LLN~ and FVC \> FVC~LLN~ or as FEV~1~/FVC≥FEV~1~/FVC~LLN~, FVC \< FVC~LLN~, and TLC \> TLC~LLN~. A diagnosis of restriction was based on FEV~1~/FVC≥FEV~1~/FVC~LLN~, FVC \< FVC~LLN~, and TLC \< TLC~LLN~, whereas a mixed defect was diagnosed if the following conditions were met: FEV~1~/FVC \< FEV~1~/FVC~LLN~, FVC \< FVC~LLN~, and TLC \< TLC~LLN~. Of note, the interpretation of PFTs was based, in our study and per ATS/ERS recommendations, on both spirometry and lung volumes, the latter being considered the gold standard and necessary differentiator test in a great number of situations.

The AEX ([Figure 1](#fig1){ref-type="fig"}) was computed by the available PFT software as the integral function of the exhalation phase of the flow--volume curve. The largest AEX value of all prebronchodilator trials has been selected. For several analyses and models, owing to its nongaussian distribution, the square root of AEX (Sqrt AEX) was used.

We built several models that evaluated the relationships between AEX and inspiratory capacity (IC), FRC, RV, and TLC. We were especially interested in assessing AEX against indices of gas trapping and hyperinflation, such as FRC/TLC or RV/TLC and IC/TLC ("inspiratory fraction"), which can only be derived from lung volume testing. The IC/TLC was shown in prior investigations to be an independent predictor of respiratory and all-cause mortality in subjects with chronic obstructive pulmonary disease. Furthermore, we resorted to several recursive partitioning models with 33% holdback for validation, by which we performed the interactive best-split procedure of the functional diagnostic categories as nominal variables. For the recursive partitioning, the following factors were used: FEV~1~, FVC, and FEV~1~/FVC percent predicted; FEV~1~, FVC, and FEV~1~/FVC *z*-scores (all determined by race, sex, age, and height); actual FEV~1~/FVC; and (Sqrt) AEX. We found that the neural network models using Sqrt AEX, FEV~1~, FVC, and FEV~1~/FVC *z*-scores performed best (i.e., highest *R*^2^ and area under the receiver operating characteristic curve, dominant pattern probability or density \>50%, minimized misclassification rates, and square root mean error).

Given the collinearity that may exist between various functional parameters, we used neural networks (machine learning algorithms) that could dynamically adjust for the relationship between variables, whereas typical regression assumes complete independence or noncollinearity of the inputs. Neural networks can efficiently and flexibly model nonlinear response surfaces. The developed neural networks had the following parameters as inputs: AEX or Sqrt AEX, percent predicted or *z-*scores of FEV~1~ and FVC. Output was represented by the functional pattern (based on the classification as normal, obstruction, restriction, or mixed defect). Neural networks were designed with two "hidden" layers, each with three sigmoidal, three linear, and three gaussian distribution nodes, squared penalty method, and up to 50 iteration tours (to avoid overfitting). Internal validation was performed with a random holdback method at a rate of 33%. Statistical significance was set at *P* \< 0.05. Analyses were performed using JMP Pro14 software (SAS Institute). The study received Institutional Review Board approvals (Cleveland Clinic IRB EX\#0504 and EX\#19-1129; Emory IRB \#00049576/Atlanta VA RD Ioachimescu-002).

Results
=======

We analyzed a total of 15,308 consecutive PFTs. Fifty-one percent of the subjects tested were men. Eighty-six percent were (self-identified) white, and 13% were African American. Only 62 subjects self-identified as Hispanic; nevertheless, GLI equations include Hispanic individuals in the same category as white individuals ([@bib2]). The mean age ± standard deviation of the analyzed subjects was 56 ± 14 years. The helium dilution technique was used to measure lung volumes in 40% of the patients (*n* = 8,501), whereas body plethysmography was used in the remaining 60% (*n* = 12,752).

The main anthropometric and functional parameters of the patients tested are shown in [Table 1](#tbl1){ref-type="table"}. By using the manufacturer's proprietary software, the largest acceptable digitally obtained AEX was analyzed ([Figure 1](#fig1){ref-type="fig"}).

###### 

Demographic characteristics and pulmonary function test measurements (*N* = 15,308)

  Parameter                    Mean ± SD     Median   25th--75th IQR
  -------------------------- -------------- -------- ----------------
  Age, yr                       56 ± 14        57        47 to 67
  Height, cm                    168 ± 10      168       161 to 175
  Weight, kg                    81 ± 21        79        66 to 94
  Body surface area, m^2^      1.9 ± 0.2      1.9       1.7 to 2.0
  Body mass index, kg/m^2^       28 ± 7        28        24 to 32
  FET, s                      12.19 ± 3.06   12.86    9.52 to 14.93
  PEF, L                      5.07 ± 2.49     4.84     3.07 to 6.76
  FVC, L                      2.94 ± 1.07     2.81     2.14 to 3.59
  FVC *z-*score               −1.69 ± 1.61   −1.56    −2.65 to −0.61
  FEV~1~, L                   1.87 ± 0.95     1.77     1.09 to 2.49
  FEV~1~*z-*score             −2.50 ± 1.8    −2.37    −3.8 to −1.13
  FEV~6~, L                   2.55 ± 1.02     2.40     1.81 to 3.07
  FEV~1~/FVC                  0.62 ± 0.19     0.62     0.47 to 0.78
  FEV~1~/FVC *z-*score        −2.31 ± 3.35   −1.59     −4.4 to 0.12
  FEV~1~/FEV~6~               0.65 ± 0.16     0.70     0.51 to 0.79
  TLC, L                      5.52 ± 1.74     5.30     4.26 to 6.57
  RV, L                       2.49 ± 1.42     2.07     1.46 to 3.18
  RV/TLC                      0.43 ± 0.15     0.41     0.32 to 0.54
  IC, L                       2.13 ± 0.83     2.03     1.52 to 2.63
  IC/TLC                      0.40 ± 0.12     0.41     0.30 to 0.49

*Definition of abbreviations*: FET = forced expiratory time; FEV~1~ = forced expiratory volume in 1 second; FEV~6~ = forced expiratory volume in 6 seconds; FVC = forced vital capacity; IC = inspiratory capacity; IQR = interquartile range; PEF = peak expiratory flow; RV = residual volume; SD = standard deviation; TLC = total lung capacity.

Using GLI predictive spirometric equations, obstruction was present in 42.6% of the tests. Among those with obstruction, the severity was deemed mild in 7%, moderate in 14%, moderately severe in 14%, severe in 22%, and very severe in 43%. Restriction was confirmed by lung volume testing in 16.5% of the tests, whereas a mixed ventilatory pattern was found in 4.5% of the data set.

The mean Sqrt AEX values were 3.32, 1.81, 2.30, and 1.64 L⋅sec^−0.5^ in normal, obstruction, restriction, and mixed patterns, respectively; all between-group differences were statistically significant at *P* \< 0.0011 levels ([Figure 2](#fig2){ref-type="fig"}). The mean Sqrt AEX values were 2.97, 2.30, 1.92, 1.46, and 0.98 L⋅sec^−0.5^ in mild, moderate, moderately severe, severe, and very severe obstruction, respectively; all between-group differences were significant at *P* \< 0.0001.

![Box-and-whisker plots of the square root of the area under the expiratory flow--volume curve (Sqrt AEX) for Global Lung Initiative (GLI)-defined obstruction, restriction, mixed ventilatory defects, or normal patterns. The numbers associated with the box plots illustrate the mean Sqrt AEX values of each group. Tukey-Kramer and Welch analysis of variance test *P* \< 0.0001; in-between group *P* values are shown on the graph. Horizontal gray line: average Sqrt AEX for the entire cohort. \*Denotes that small airway disease was not considered as a separate disease category. Color codes: green = normal; red = obstruction; blue = restriction; purple = mixed ventilatory defect (all patterns as determined by GLI predictive equations for spirometry).](AnnalsATS.201908-613OC_f2){#fig2}

To assess the ability of AEX to avoid lung volume testing (at least in some cases), we explored the relationship between AEX and IC, IC/TLC, or RV/TLC. As such, in a linear model, the Sqrt AEX was able to predict with good accuracy the IC ([Figure 3A](#fig3){ref-type="fig"}). A third-degree polynomial relationship between IC/TLC and Sqrt AEX ([Figure 3B](#fig3){ref-type="fig"}) explained approximately two-thirds of the parameter's variance (*R*^2^ = 0.62), whereas a quartic fit (fourth-degree polynomial fit) between RV/TLC and Sqrt AEX explained up to three-fourths of the variance (*R*^2^ = 0.74) ([Figure 3C](#fig3){ref-type="fig"}). As shown in [Figures 3A--3C](#fig3){ref-type="fig"}, our cohort included a significant number of patients with very severe obstruction and air trapping, the majority of them being part of a severe emphysema trial.

![(*A*) Bivariate linear fit of inspiratory capacity (IC) by the square root of the area under the expiratory flow--volume curve (Sqrt AEX). The 50% ellipses are shown for the different Global Lung Initiative (GLI)-defined patterns. (*B*) Bivariate cubic fit of Sqrt AEX by IC/total lung capacity (TLC). (*C*) Bivariate quartic fit of residual volume (RV)/TLC ratio by Sqrt AEX. Color codes: green = normal pattern; red = obstruction; blue = restriction; purple = mixed ventilatory defect; light green = small airway disease (all using GLI reference equations). RMSE = root mean square error.](AnnalsATS.201908-613OC_f3){#fig3}

A simple best-split partition of the diagnostic categories by using FVC and FEV~1~ GLI *z*-scores (sex, race, height, and age adjusted) and Sqrt AEX led to a slightly better model performance (Δ*R*^2^ = 0.01--0.02 and lower misclassification rates) than that of the one based on Sqrt AEX plus GLI-based percent predicted FEV~1~ and FVC. In [Figure 4](#fig4){ref-type="fig"}, we show the expected probabilities of various patterns by using the indicated algorithm in this sample. The model was developed on the basis of 66.6% of the data set (*R*^2^ = 0.47) and validated on the basis of 33.3% of the tests (*R*^2^ = 0.46). The area under the receiver operating characteristic curve values in both training and validation sets were as follows: 0.98 (in obstruction, restriction, and mixed patterns) and 0.99 (in normal tests).

![Seven-split partition as a proposed pulmonary function test interpretation algorithm based on forced vital capacity (FVC) *z*-score, forced expiratory volume in 1 second (FEV~1~) *z*-score, and the square root of the area under the expiratory flow--volume curve (Sqrt AEX). Pattern probability or density refers to the percentage of subjects with the actual spirometric diagnostic categories.](AnnalsATS.201908-613OC_f4){#fig4}

We also used machine learning (neural network) models to predict the type of GLI-defined ventilatory impairments or patterns ([Figure 5](#fig5){ref-type="fig"}). We used as inputs FEV~1~, FVC, and FEV~1~/FVC ratio *z-*scores (per GLI equations), with or without Sqrt AEX. The model using all four variables showed better performance in differentiating various ventilatory patterns (i.e., lower misclassification rates against standard classifications based on FVC, FEV~1~/FVC, and TLC): 8.7% in the training set and 8.4% in the validation set. The lowest concordance rate was for mixed ventilatory defects (48--53%), most of which were misclassified as obstructive patterns. The addition of Sqrt AEX to FEV~1~, FVC, and FEV~1~/FVC ratio *z-*scores (based on GLI equations) improved overall diagnostic performance by a relatively modest Δ*R*^2^ of 0.01, but, more important, it improved mixed pattern misclassification rates by approximately 20% and 22% in the derivation and validation sets, respectively.

![Machine learning (neural network) model predicting the type of Global Lung Initiative (GLI)-defined ventilatory impairment (output), using forced expiratory volume in 1 second (FEV~1~), forced vital capacity (FVC), and FEV~1~/FVC *z*-scores (GLI predicted) and square root transformation of the area under the expiratory flow--volume curve (Sqrt AEX) as inputs. The middle portion of the figure shows the architecture of the neural network, with three inputs, one output, and two layers of intermediary or "hidden" nodes (three linear, three sigmoidal, and three normal distributions). The model showed high performance in differentiating among various ventilatory impairment patterns (*R*^2^ = 0.949), with low misclassification rates. The confusion or reclassification matrix summarizes the accuracy and misclassification rates of the model in each actual category. AUROC = area under the receiver operating characteristic curve; RMSE = root mean square error.](AnnalsATS.201908-613OC_f5){#fig5}

Discussion
==========

The main finding of this study in a large sample of PFTs is that, in combination with traditional spirometric parameters such as FEV~1~, FVC, and FEV~1~/FVC ratio *z-*scores, AEX performs well in stratifying, both clinically and statistically, the main types and degrees of physiologic derangement, with low overall rates of misclassification (\<9%) compared with traditional PFT diagnostic categories.

The appeal of such a parameter is based on the limitations of current interpretive strategies for PFTs. For example, an obstructive ventilatory defect is currently defined by the ATS/ERS Task Force for Standardization of Lung Function Testing ([@bib6]) as a reduced FEV~1~/FVC ratio (i.e., below the fifth percentile of the predicted value). However, it is well known that the earliest changes associated with airflow obstruction in small airways can be seen in the last portion of the flow--volume diagram (with a "concave" or "coved" appearance of the curve), even when the initial portion of FEV~1~ is still normal. As another limitation of current interpretive strategies, a restrictive ventilatory defect is defined as having a TLC below the LLN or the fifth percentile of the predicted value, together with a normal FEV~1~/FVC ratio. Volumes are typically determined either by gas dilution (e.g., helium method) or by body plethysmography techniques. In practice, spirometry is commonly able to "suggest" restriction, recognizing that a low FVC can reflect either true restriction, airflow obstruction with excessive air trapping and secondary capacity reduction, or early termination of the expiratory effort during the spirometric maneuvers. On this basis, we know that spirometry is generally not able to definitively rule in or rule out restriction, and lung volume determination is generally required ([@bib17]). Furthermore, a mixed ventilatory defect is characterized by both obstruction and restriction and defined functionally when both FEV~1~/FVC and TLC are below the fifth percentiles of their predicted values or LLN. As such, because obstructive and restrictive defects can both present with reduced FVC, the presence of a restrictive component in a patient with airflow limitation ("obstructed") cannot always be inferred from the FEV~1~ and FEV~1~/FVC ratio.

To date, several studies have addressed the possible utility of AEX ([@bib8], [@bib11], [@bib18]--[@bib22]). Bunn and colleagues assessed the use of an analog version of AEX and compared it with predicted values based on peak expiratory flow and FVC ([@bib8], [@bib18]). This was, in fact, almost identical to what we described later as AEX~1~ ([@bib12]). Most studies have addressed pediatric testing (because younger subjects may encounter difficulty comprehending or following instructions), bronchodilator or bronchoconstrictor responses, assessment of "airway patency," or AEX used as a surrogate marker for FEV~1~ (also in children) ([@bib10], [@bib11], [@bib20]--[@bib22]). Vermaak and colleagues examined the AEX in 60 adult South African subjects without a history of lung disease and derived AEX predictive equations; the study lacked a validation group ([@bib19]). Four decades later, other authors found that digitally obtained AEX correlated well with hyperinflation in subjects with chronic obstructive pulmonary disease ([@bib23]), confirming the utility of AEX as a global functional respiratory parameter. Our group is currently in the process of validating predictive equations for AEX, which will allow us in the future to determine age, height, sex, and height-determined AEX *z-*scores, potentially useful in further refinements of diagnostic classifications and severity stratification.

Extending these prior studies that examined AEX in narrow clinical settings or in much smaller populations, in several investigations conducted by our group ([@bib9], [@bib12]), we have used digital AEX or its approximations as global spirometric measurements of ventilatory impairment in large samples of adults. In these subjects, we validated the existence of obstruction, mixed, or restrictive ventilatory defects by using the gold standard test (i.e., lung volume determination by body plethysmography or by the helium dilution method).

Several limitations of the present study warrant comment. The equations derived (e.g., [Figures 3](#fig3){ref-type="fig"} and [5](#fig5){ref-type="fig"}) are based on a hypothesis-generating set and require validation in an independent, external data set. In addition, the effort to find a better standard for ventilatory impairments such as obstruction, restriction, mixed patterns, or even small airway disease has inherent limitations. For example, the newly proposed measurement may correlate poorly with "imperfect" traditional parameters; it can have significant dependencies (e.g., to FVC) and/or wide coefficients of variation. In this setting, there is still a need to derive and to validate normative data for AEX, a parameter likely influenced by sex, race, height, and possibly even by weight.

The appeal of using neural networks that use spirometric parameters stems from their extraordinary ability in the areas of information processing, their nonlinearity and noise acceptance, and acquisition ("machine learning") and generalization capabilities beyond visible or observable patterns. In contrast to the traditional tools, they offer model-free, adaptive parallel processing and great tolerance for errors, outliers, and data artifacts, which makes them also ideal for normative data derivation in different populations.

Conclusions
-----------

The present paper presents the proof of concept and a performance analysis of AEX as an additional instrument derived from spirometry. We found that, in combination with other spirometric measurements, the use of AEX is able to differentiate among traditional diagnostic patterns (normal, obstruction, restriction, or mixed defects). In addition, the AEX could predict with reasonable accuracy IC, IC/TLC, and RV/TLC, potentially obviating the need for more advanced lung function testing such as body plethysmography or gas dilution methods to diagnose hyperinflation, restriction, or mixed defects. Last, using machine learning algorithms with spirometric inputs such as FEV~1~, FVC, and FEV~1~/FVC ratio *z-*scores in addition to Sqrt AEX significantly improves diagnostic classifications. The low rates of misclassification obtained with this model against traditional functional categories could potentially be employed in epidemiological or population screening studies, in which lung volume determination by body plethysmography or other methods is not practical and spirometry is often the only available testing modality. Further study is needed to validate these findings in larger, independent data sets and to better characterize the relationship between AEX profiles and specific disease endophenotypes.
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